Opioids in cancer pain: Common dosing errors

ONCOLOGY

Volumn 17, Issue 4, 2003, Pages 571-575

  Romeen, Kochhar ^d   Legrand, Susan B ^d   Walsh, Declan ^a   Davis, Mellar P ^d   Lagman, Ruth ^b   Rivera, Nilo I ^c  

^a Palliative Medicine   (United Kingdom)

^b Clinical Services   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

HUMAN; INTRACTABLE PAIN; NEOPLASM; REVIEW;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN, INTRACTABLE;

EID: 70449999903     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Ventafridda V, Tamburini M, Caraceni A, et al: A validation study of the WHO method for cancer pain relief. Cancer 59:850-856, 1987.
2. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50:1913- 1918, 1982.
3. Donnelly S, Davis MP, Walsh D, et al: Morphine in cancer pain management: A practical guide. Support Care Cancer 10:13-35, 2002.
4. Ripamonti C, Dickerson ED: Strategies for the treatment of cancer pain in the new millennium. Drugs 61: 955-977, 2001.
5. Cleeland CS, Gonin R, Hatfield AK, et al: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-596, 1994.
6. Larue F, Colleau SM, Brasseur L, et al: Multicentre study of cancer pain and its treatment in France. BMJ 310:1034-1037, 1995.
7. Walsh D: Oral morphine in chronic pain. Pain 18:1-11, 1984.
8. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 81:129-134, 1999.
9. Bruera E, Macmillan K, Kuehn N, et al: Orcadian distribution of extra doses of narcotic analgesics in patients with cancer pain: A preliminary report. Pain 49:311-314, 1992.
10. Sarhill N, Walsh D, Davis MP: Intermittent pain in advanced cancer: Incident and breakthrough. Presented at the 7th Congress of the European Association for Palliative Care (EAPC); Palermo, Italy; April 2001.
11. Portenoy RK, Payne R, Coluzzi P, et al: Oral transmucosal fentanyl citrate (OFTC) for the treatment of breakthrough pain in cancer patients; a controlled dose titration study. Pain 79:303-312, 1999.
12. Zeppetella G: Sublingual fentanyl citrate for cancer-related breakthrough pain: A pilot study. PalliatMed 15:323-328, 2001.
13. Walsh D: Pharmacological management of cancer pain. Semin Oncol 27:45-63, 2000.
14. Jaffe JH: Opioid analgesics and antagonists, in Gilman AG, Goodman LS, Rail TW, et al (eds): Goodman and Gilman's The Pliarma- cological Basis ofTlierapeutics, 7th ed, pp 494- 534. New York, Macmillan, 1985.
15. Davis M, Wilcock A: Modified release opioids. Eur J Palliative Care 8:142-146, 2001.
16. Warfield CA: Controlled-release morphine tablets in patients with chronic cancer pain: A narrative review of controlled clinical trials. Cancer 82:2299-2306, 1998.
17. Pereira J, Lawlor P, Vigano A, et al: Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 22:672-687, 2001.
18. Indelicato RA, Portenoy RK: Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20:348-352, 2002.
19. Chemy N, Ripamonti C, Pereira I, et al: Strategies to manage adverse effects of oral morphine: An evidence-based report. J Clin Oncol 19:2542-2554, 2001.